electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
2024年8月3日 - 5:05AM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine and wellness company, today
announced that on August 1, 2024, Stephen Smith joined electroCore
as the Company’s VP, Quality, Regulatory, and Compliance, and the
Compensation Committee of electroCore’s Board of Directors granted
10,000 restricted stock units (“RSUs”) to Mr. Smith in connection
with the commencement of his employment. The RSUs were granted as
an inducement material to Mr. Smith’s commencement of employment
pursuant to NASDAQ Listing Rule 5635(c)(4). 33% of the RSUs will
vest on each of the first, second and third anniversaries of the
date of grant, subject to Mr. Smith’s continued employment by the
Company on the applicable vesting date.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine
and wellness company dedicated to improving health and promoting
general wellness through its non-invasive vagus nerve stimulation
(“nVNS”) technology platform. The company’s is focused on the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
過去 株価チャート
から 8 2024 まで 9 2024
electroCore (NASDAQ:ECOR)
過去 株価チャート
から 9 2023 まで 9 2024